Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma

Bibliography

• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8(3):641-61
   PubMed Web of Science ®Google Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17(5):421-33
   PubMed Web of Science ®Google Scholar
• Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976;20(8):1127-39
   Google Scholar
• Muggia FM, Creaven PJ, Hansen HH, Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56(4):515-21
   PubMedGoogle Scholar
• Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75(6):1262-71
   PubMed Web of Science ®Google Scholar
• Van Hattum AH, Pinedo HM, Schluper HM, New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000;88(2):260-6
   PubMed Web of Science ®Google Scholar
• Boven E, Van Hattum AH, Hoogsteen I, New analogues of camptothecins. Activity and resistance. Ann NY Acad Sci 2000;922:175-7
   PubMed Web of Science ®Google Scholar
• Yao S, Murali D, Seetharamulu P, Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res 1998;58(17):3782-6
   PubMed Web of Science ®Google Scholar
• Van Hattum AH, Schluper HMM, Hausheer FH, Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 2002;100(1):22-9
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, Tohgo A, Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7(4):935-41
   PubMed Web of Science ®Google Scholar
• Thompson PA, Berg SL, Aleksic A, Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol 2004;53(6):527-32
   PubMed Web of Science ®Google Scholar
• Keir ST, Hausheer F, Lawless AA, Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 2001;48(1):83-7
   PubMed Web of Science ®Google Scholar
• Viros A, Fridlyand J, Bauer J, Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;5(6):e120
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [Internet]. N Engl J Med 2011; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21639808 [ [Cited 26 June 2011]
   Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467(7315):596-9
   PubMed Web of Science ®Google Scholar
• Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci 2006;11:1-14
   PubMed Web of Science ®Google Scholar
• Fong L, Kwek SS, O'Brien S, Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69(2):609-15
   PubMed Web of Science ®Google Scholar
• Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 2008;3(2):105-13
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 2008;8(10):1583-93
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010;2:197-211
   PubMedGoogle Scholar
• Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration. - ASCO [Internet].. [date unknown];[cited 15:50:21] Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=200862
   Google Scholar
• Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration. - ASCO [Internet]. [date unknown];[cited 15:50:22] Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=200862
   Google Scholar
• Daud A, Valkov N, Centeno B, Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 2005;11(8):3009-16
   PubMed Web of Science ®Google Scholar
• Munster P, Marchion D, Bicaku E, Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25(15):1979-85
   PubMed Web of Science ®Google Scholar
• Grossman SA, Carson KA, Phuphanich S, Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-oncol 2008;10(4):608-16
   PubMed Web of Science ®Google Scholar
• Daud AI, Dawson J, DeConti RC, Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009;15(7):2479-87
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Sill MW, Ramirez PT, Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2008;18(3):460-4
   PubMed Web of Science ®Google Scholar
• Miller AA, Herndon JE, Gu L, Green MR. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer 2005;48(3):399-407
   PubMed Web of Science ®Google Scholar